Products for Research Use Only
RegisterLogin

KD025

CAT: 0013-GTR19159266-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19159266-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SLx-2119, also known as KD-025, is an orally bioavailable inhibitor of ROCK-II that is greater than 200-fold selective over ROCK-I (IC50s = 105 nM and 24 μM, respectively) . (In Vitro) :Belumosudil (SLx-2119; 40 μM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with Belumosudil, shows a 5-times higher background than the other arrays. (In Vivo) :Belumosudil (KD-025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. Belumosudil is at least as efficacious in aged, diabetic or female mice, as in normal adult males.
CAS Number
911417-87-3
Product Name Alternative
SLx-2119 | SLx2119 | SLx 2119 | KD 025
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 29 mg/mL; 64.09 mM
Smiles
C (=O) (COc1cc (ccc1) c1nc2c (c (n1) Nc1cc3cn[nH]c3cc1) cccc2) NC (C) C
Molecular Formula
C26H24N6O2
Molecular Weight
452.51
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-[3-[4- (1H-indazol-5-ylamino) -2-quinazolinyl]phenoxy]-N- (1-methylethyl) -acetamide

Related Products

CatalogName
GTR19212035-01KD026-metabolite

Alternative Products

CatalogName
M19254-01KD025
S7936-10mM/1mLBelumosudil (KD025)
MBS3840950-01SLx-2119 (KD025)
MBS579393KD025 (SLx-2119)
A15239-50SLx-2119 (KD025) 50mg
A15239-500SLx-2119 (KD025) 500mg
A15239-25SLx-2119 (KD025) 25mg
A15239-2SLx-2119 (KD025) 2mg
A15239-10mM-DSLx-2119 (KD025) 10mM * 1mL in DMSO

Popular Products